查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1961430

口服固态製剂契约製造市场－全球产业规模、份额、趋势、机会和预测：按产品、最终用户、地区和竞争对手划分，2021-2031年

Oral Solid dosage Contract Manufacturing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球口服固态製剂（OSD）契约製造市场预计将从 2025 年的 410.2 亿美元大幅成长至 2031 年的 607.7 亿美元，复合年增长率为 6.77%。

在这个领域，片剂和胶囊等固态剂型的生产外包给专业的第三方供应商。推动该市场发展的主要因素是製药公司为提高成本效益、获取复杂化合物的先进技术所做的努力，而这些技术无需大量的资本投入。此外，随着主要药物专利到期，提高外部生产能力以应对学名药的大规模生产变得至关重要。根据美国可及药品协会（Association for Accessible Medicines）预测，到2024年，学名药和生物类似药将占美国所有处方笺的90%，凸显了推动契约製造产业发展的巨大需求。

市场概览
预测期 2027-2031
市场规模：2025年 410.2亿美元
市场规模：2031年 607.7亿美元
复合年增长率：2026-2031年 6.77%
成长最快的细分市场 颗粒
最大的市场 北美洲

然而，由于全球法规环境严格，该产业面临许多挑战。契约製造製造商必须遵守各项国际品质标准，这需要投入大量且持续的资源。这些法规的复杂性可能导致核准流程冗长，并增加供应链的脆弱性，可能阻碍市场的持续成长。

市场驱动因素

推动市场成长的主要动力是中小型生物製药研发公司的增加，这从根本上改变了外包格局。与传统的大型製药企业不同，这些新兴企业通常拥有强大的研发管线，但缺乏商业规模固态製剂生产所需的资本密集基础设施。因此，它们正与契约製造建立策略合作伙伴关係，以在无需承担高额固定成本的情况下推动研发。对早期药物发现研究的大力投资进一步强化了这种依赖。根据Harris Williams R&D 2024年8月发布的报告《製药合约服务：新数据显示復苏迹象》，生技公司和中小製药公司的研发支出预计将成长9%至12%，超过大型产业参与者的成长速度。这种资金流入直接转化为固体製剂供应商合约量的增加，这些供应商能够提供灵活的端到端开发服务。

同时，处理高活性药物原料药(HPAPI) 和复杂製剂技术的能力不断提升，正在重塑产业的技术需求。随着现代药物研发转向癌症治疗和罕见疾病治疗，分子活性不断增强，但生物利用度低使得製剂开发面临挑战，迫使製造商投资于专用密闭设备和先进的增溶技术。根据龙沙公司于 2025 年 1 月发布的《2024 财年全年报告》，该公司小分子业务在 2024 年实现了 9.3% 的销售成长。这一业绩得益于其产品组合持续向提供高以金额为准、复杂服务转型。传统化学的持续主导地位也支撑了这一趋势。龙沙公司预计，到 2025 年，小分子化合物仍将占全球临床开发平臺中所有分子的 54%，这需要持续的专业化生产能力。

市场挑战

全球口服固态製剂（OSD）契约製造市场不断扩张，但在应对严格的全球法规环境方面面临着许多挑战。由于合约研发生产机构（CDMO）的业务遍及多个司法管辖区，它们必须遵守各国卫生监管机构制定的不同品质标准和文件要求。这种分散性导致企业需要维持大规模的品质保证团队，并且常常需要重复的测试通讯协定，从而显着增加营运成本并降低利润率。因此，原本可以用于扩大产能或升级设施的资源，但现在却不得不用于维持持续的合规性。

监管压力日益增加，这点从近期有关设施监管的行业数据中可见一斑。据欧洲製药工业协会联合会（EFPIA）称，2024年因特定合规问题而进行的「基于理由」的检查和评估频率将比上一年翻一番。监管力道的迅速加强造成了不稳定的商业环境，核准进度难以预测。这种不确定性阻碍了製造商按时交付的能力，并最终限制了他们高效拓展市场以满足不断增长的全球需求的能力。

市场趋势

连续生产技术的快速普及正在从根本上改变口服固态製剂的生产环境，以完全整合的流式系统取代传统的间歇式生产流程。这种营运模式的转变使契约製造製造商能够大幅缩短研发时间和减少生产面积，同时透过即时监控提高产品品质。这些能力对于处理日益增多的精准药品和实现灵活的小批量生产至关重要。根据Hovione公司2025年10月发布的新闻稿《Hovione完成新泽西州製造地业务扩张的首期1亿美元投资》，该公司已完成大规模的设施扩建项目，该项目明确整合了商业规模的连续片剂生产能力，以满足其北美製药客户不断变化的技术需求。

此外，随着越来越多的公司寻求降低地缘政治风险并减少对分散的全球网路的依赖，策略性地将生产供应链迁回国内或近岸外包已成为行业优先事项。这一趋势正促使口服固态製剂产能大规模转移至美国和欧洲的国内工厂，以确保基本药物的稳定供应。因此，大型製药企业正在对当地基础设施进行巨额投资，以建立强大且永续的生产生态系统。根据Think Global Health于2025年11月发表的题为《追踪美国为规避关税而进行的本土化进展》的报导，13家领先的製药公司已联合承诺在未来十年内投资超过4800亿美元，以扩大其在美国的生产能力。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球口服固态製剂（OSD）契约製造市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 产品类型（片剂、胶囊、粉末、颗粒剂、其他）
    • 按最终用户划分（大型企业、中小企业、Start-Ups、学名药生产商）
    • 按地区
    • 按公司（2025 年）
  • 市场地图

第六章：北美口服固态製剂（OSD）契约製造市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国别分析
    • 我们
    • 加拿大
    • 墨西哥

第七章：欧洲口服固态製剂（OSD）契约製造市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国别分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区口服固态製剂（OSD）契约製造市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国别分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：中东和非洲口服固态製剂（OSD）契约製造市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东与非洲：国别分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章：南美洲口服固态製剂（OSD）契约製造市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国别分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 促进因素
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 近期趋势

第十三章 全球口服固态製剂（OSD）契约製造市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的议价能力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • AbbVie Inc.
  • Acino International AG
  • Aenova Holding GmbH
  • Beximco Pharmaceuticals Ltd
  • Boehringer Ingelheim International GmbH
  • Catalent Inc.
  • Corden Pharma International GmbH,
  • PerkinElmer Inc.
  • Pyramid Laboratories Inc.
  • Siegfried AG

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 18969

The Global Oral Solid dosage (OSD) Contract Manufacturing Market is projected to expand significantly, growing from USD 41.02 Billion in 2025 to USD 60.77 Billion by 2031, representing a CAGR of 6.77%. This sector involves the outsourcing of solid drug formulation production, including tablets and capsules, to specialized third-party vendors. The market is primarily driven by pharmaceutical companies aiming to achieve cost efficiencies and access advanced technologies for complex compounds without incurring heavy capital expenditures. Furthermore, the expiration of patents for major drugs has necessitated increased external capacity to handle high-volume generic production. According to the Association for Accessible Medicines, generic and biosimilar medicines accounted for 90% of all prescriptions filled in the United States in 2024, highlighting the critical volume demand fueling the contract manufacturing sector.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 41.02 Billion
Market Size 2031USD 60.77 Billion
CAGR 2026-20316.77%
Fastest Growing SegmentGranules
Largest MarketNorth America

However, the industry faces significant hurdles due to a stringent global regulatory environment. Contract manufacturers are required to maintain compliance with divergent international quality standards, which necessitates substantial and ongoing resource allocation. This regulatory complexity can lead to prolonged approval timelines and vulnerabilities within the supply chain, acting as a potential barrier to the market's sustained expansion.

Market Driver

A primary engine for market growth is the proliferation of small and mid-sized biopharmaceutical innovators, which is fundamentally transforming the outsourcing landscape. Unlike traditional large pharmaceutical entities, these emerging firms typically possess robust research pipelines but lack the capital-intensive infrastructure necessary for commercial-scale solid dose production. Consequently, they form strategic partnerships with contract manufacturers to navigate development phases without facing high fixed costs. This reliance is intensified by aggressive investment in early-stage discovery; according to the August 2024 report 'Outsourced Pharma Services: New Data Shows Resurgence Is Underway' by Harris Williams, R&D spending for biotech and small to mid-sized pharmaceutical companies is projected to increase by 9% to 12%, outpacing the growth rate of larger industry players. This capital influx directly translates into higher contract volumes for OSD providers capable of offering flexible, end-to-end development services.

Simultaneously, the expansion of capabilities for High-Potency Active Pharmaceutical Ingredients (HPAPIs) and complex formulations is reshaping technical requirements within the sector. As modern drug discovery shifts toward oncology and rare diseases, molecules are becoming increasingly potent and challenging to formulate due to poor bioavailability, compelling manufacturers to invest in specialized containment and advanced solubility enhancement technologies. In its 'Full-Year Report 2024' released in January 2025, Lonza reported that its Small Molecules division achieved sales growth of 9.3% in 2024, a performance driven by the continued portfolio shift toward high-value, complex service offerings. This trend is underpinned by the enduring dominance of traditional chemistries; according to Lonza, in 2025, small molecules continue to comprise 54% of all molecules in the global clinical development pipeline, necessitating sustained specialized manufacturing capacity.

Market Challenge

The expansion of the Global Oral Solid Dosage (OSD) Contract Manufacturing Market faces a formidable obstacle in navigating a stringent global regulatory environment. As contract development and manufacturing organizations (CDMOs) operate across multiple jurisdictions, they must align with divergent quality standards and documentation requirements enforced by different national health authorities. This fragmentation necessitates the maintenance of extensive quality assurance teams and often requires duplicative testing protocols, which significantly increases operational costs and erodes profit margins. Consequently, resources that could be invested in capacity expansion or facility upgrades are instead diverted toward maintaining continuous compliance.

The intensifying pressure of this regulatory burden is evident in recent industry data regarding facility oversight. According to the European Federation of Pharmaceutical Industries and Associations (EFPIA), in 2024, the frequency of 'for cause' inspections-assessments triggered by specific compliance concerns-doubled compared to the previous year. This sharp increase in regulatory scrutiny creates a volatile operating environment where approval timelines are unpredictable. Such uncertainty hampers the ability of manufacturers to guarantee strict delivery schedules, ultimately constraining the market's ability to scale efficiently in response to rising global demand.

Market Trends

The accelerated adoption of continuous manufacturing technologies is fundamentally changing the production landscape for oral solid dosages by replacing traditional batch processes with fully integrated flow systems. This operational shift allows contract manufacturers to significantly reduce development timelines and footprint requirements while enhancing product quality through real-time monitoring. Such capabilities are increasingly critical for handling the growing volume of precision medicines and facilitating flexible small-volume production. According to Hovione's October 2025 press release, 'Hovione Completes Initial $100M Investment Cycle to Expand U.S. Operations at New Jersey Manufacturing Site,' the company finalized a major facility expansion that explicitly integrates commercial-scale continuous tableting capacity to meet the evolving technical demands of North American pharmaceutical clients.

Additionally, strategic reshoring and nearshoring of manufacturing supply chains have become a primary priority for the industry as companies seek to mitigate geopolitical risks and reduce dependency on fragmented global networks. This trend is driving a substantial migration of oral solid dosage production capacity back to domestic hubs in the United States and Europe to ensure supply security for essential medicines. Consequently, large pharmaceutical entities are directing massive capital inflows into local infrastructure to establish robust and self-reliant production ecosystems. According to the November 2025 article 'Tracking Pharma's Progress on U.S. Onshoring Efforts to Avoid Tariffs' by Think Global Health, thirteen major pharmaceutical companies have collectively pledged more than $480 billion in investments toward expanding U.S. manufacturing capabilities over the next decade.

Key Market Players

  • AbbVie Inc.
  • Acino International AG
  • Aenova Holding GmbH
  • Beximco Pharmaceuticals Ltd
  • Boehringer Ingelheim International GmbH
  • Catalent Inc.
  • Corden Pharma International GmbH,
  • PerkinElmer Inc.
  • Pyramid Laboratories Inc.
  • Siegfried AG

Report Scope

In this report, the Global Oral Solid dosage (OSD) Contract Manufacturing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Oral Solid dosage (OSD) Contract Manufacturing Market, By Product

  • Tablets
  • Capsules
  • Powders
  • Granules
  • Others

Oral Solid dosage (OSD) Contract Manufacturing Market, By End User

  • Large-size companies
  • Small & medium size companies
  • Startups
  • generic pharmaceutical companies

Oral Solid dosage (OSD) Contract Manufacturing Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Oral Solid dosage (OSD) Contract Manufacturing Market.

Available Customizations:

Global Oral Solid dosage (OSD) Contract Manufacturing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Oral Solid dosage (OSD) Contract Manufacturing Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Tablets, Capsules, Powders, Granules, Others)
    • 5.2.2. By End User (Large-size companies, Small & medium size companies, Startups, generic pharmaceutical companies)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Oral Solid dosage (OSD) Contract Manufacturing Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By End User
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Oral Solid dosage (OSD) Contract Manufacturing Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By End User
    • 6.3.2. Canada Oral Solid dosage (OSD) Contract Manufacturing Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By End User
    • 6.3.3. Mexico Oral Solid dosage (OSD) Contract Manufacturing Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By End User

7. Europe Oral Solid dosage (OSD) Contract Manufacturing Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By End User
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Oral Solid dosage (OSD) Contract Manufacturing Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By End User
    • 7.3.2. France Oral Solid dosage (OSD) Contract Manufacturing Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By End User
    • 7.3.3. United Kingdom Oral Solid dosage (OSD) Contract Manufacturing Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By End User
    • 7.3.4. Italy Oral Solid dosage (OSD) Contract Manufacturing Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By End User
    • 7.3.5. Spain Oral Solid dosage (OSD) Contract Manufacturing Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By End User

8. Asia Pacific Oral Solid dosage (OSD) Contract Manufacturing Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By End User
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Oral Solid dosage (OSD) Contract Manufacturing Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By End User
    • 8.3.2. India Oral Solid dosage (OSD) Contract Manufacturing Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By End User
    • 8.3.3. Japan Oral Solid dosage (OSD) Contract Manufacturing Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By End User
    • 8.3.4. South Korea Oral Solid dosage (OSD) Contract Manufacturing Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By End User
    • 8.3.5. Australia Oral Solid dosage (OSD) Contract Manufacturing Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By End User

9. Middle East & Africa Oral Solid dosage (OSD) Contract Manufacturing Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By End User
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Oral Solid dosage (OSD) Contract Manufacturing Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By End User
    • 9.3.2. UAE Oral Solid dosage (OSD) Contract Manufacturing Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By End User
    • 9.3.3. South Africa Oral Solid dosage (OSD) Contract Manufacturing Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By End User

10. South America Oral Solid dosage (OSD) Contract Manufacturing Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By End User
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Oral Solid dosage (OSD) Contract Manufacturing Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By End User
    • 10.3.2. Colombia Oral Solid dosage (OSD) Contract Manufacturing Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By End User
    • 10.3.3. Argentina Oral Solid dosage (OSD) Contract Manufacturing Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Oral Solid dosage (OSD) Contract Manufacturing Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. AbbVie Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Acino International AG
  • 15.3. Aenova Holding GmbH
  • 15.4. Beximco Pharmaceuticals Ltd
  • 15.5. Boehringer Ingelheim International GmbH
  • 15.6. Catalent Inc.
  • 15.7. Corden Pharma International GmbH,
  • 15.8. PerkinElmer Inc.
  • 15.9. Pyramid Laboratories Inc.
  • 15.10. Siegfried AG

16. Strategic Recommendations

17. About Us & Disclaimer